Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size, Share, Growth Analysis, By Indication(Cancer, Autoimmune Diseases), By Technology(Bifunctional and Monovalent), By End-User(Pharmaceutical Companies, Academic and Research Institutions) - Industry Forecast 2024-2031

Proteolysis-targeting Chimeric Molecules (PROTACs) Market size was valued at USD 103.31 million in 2021 and is poised to grow from USD 113.85 million in 2022 to USD 247.61 million by 2030, growing at a CAGR of 10.2% in the forecast period (2023-2030).

Global Proteolysis-targeting chimeric molecules (PROTACs) market is characterized by several companies operating in the market, with different levels of market share and specialization. Competition of PROTACs is currently limited, with a few key players dominating the market. Arvinas, a biotech company, has emerged as a leader in the development of PROTACs, with several candidates in preclinical and clinical stages of development. Other companies, such as C4 Therapeutics and Kymera Therapeutics, have also entered the PROTACs space, with multiple candidates in various stages of development. Despite the limited competition, the potential for PROTACs to address previously undruggable targets has garnered significant attention from pharmaceutical companies, leading to numerous partnerships and collaborations in the field. Additionally, the development of PROTACs has spurred interest in related technologies, such as molecular glues and protein degraders, further expanding the competitive landscape of this emerging field. 'AbbVie Inc.', 'Arvinas, Inc.', 'AstraZeneca plc', 'Bayer AG', 'Bristol Myers Squibb Company', 'C4 Therapeutics, Inc.', 'Cullgen Inc.', 'Daiichi Sankyo Co., Ltd.', 'GlaxoSmithKline plc', 'Gilead Sciences, Inc.', 'Kymera Therapeutics, Inc.', 'Merck & Co., Inc.', 'Nurix Therapeutics, Inc.', 'Novartis AG', 'Pfizer Inc.', 'Proteolix, Inc.', 'Progenra, Inc.', 'Sanofi S.A.', 'Takeda Pharmaceutical Company Limited', 'Zenith Epigenetics Ltd.', 'In March 2023, Aileron Therapeutics announced the initiation of a Phase 1 clinical trial of its ALRN-6924 ProTac for the treatment of advanced solid tumors. The trial will evaluate the safety and efficacy of the drug in combination with chemotherapy.', 'In February 2022, Zentalis Pharmaceuticals announced positive preliminary data from a Phase 1 clinical trial of its ZN-c3 ProTac for the treatment of solid tumors. The trial showed promising safety and efficacy data, with several patients experiencing partial responses.', 'In January 2022, Vividion Therapeutics announced a $135 million series D financing round to advance its platform for developing small-molecule protein degraders, including ProTacs. The funds will be used to advance multiple drug candidates into the clinic.', 'In December 2021, Kymera Therapeutics announced positive preclinical data for its lead ProTac candidate, KYM-001, for the treatment of solid tumors. The drug demonstrated significant tumor growth inhibition in multiple preclinical models.', 'In November 2021, Nurix Therapeutics announced a collaboration with Gilead Sciences to develop novel ProTacs for the treatment of cancer and other diseases. The partnership will leverage Nurix's expertise in protein degradation and Gilead's experience in drug development.'

One of the major drivers behind the development of PROTACs is the need for increased target specificity in drug design. Conventional small-molecule drugs are often non-specific, and may target multiple proteins, leading to off-target effects and toxicity. PROTACs, on the other hand, are designed to specifically target a single protein or even a specific domain within a protein, reducing the risk of unintended effects. This increased target specificity not only enhances the safety profile of PROTACs but also allows for the development of therapies for diseases that were previously untreatable.

One key market trend in the PROTACs market is the increasing adoption of this technology in drug development. PROTACs offer a new approach to drug development by targeting disease-causing proteins for degradation rather than inhibition. This technology has the potential to provide better therapeutic outcomes, especially in diseases where current treatments have limited efficacy. As a result, there is a growing interest in PROTACs from pharmaceutical companies, academic and research institutions, and contract research organizations. Additionally, there is an increasing focus on research and development, which is expected to drive the growth of the market.

North America is one of the largest markets for PROTACs, with the United States being the dominant country in the region. The market is expected to grow significantly due to the increasing number of biotechnology and pharmaceutical companies in the region and the growing interest in targeted therapies for cancer and other diseases. The dominant players in the North American PROTACs market include Arvinas, C4 Therapeutics, Nurix, and Kymera Therapeutics. These companies are focused on developing PROTACs for a wide range of indications, including cancer, inflammatory diseases, and neurodegenerative diseases. Arvinas, in particular, has been successful in advancing its lead PROTAC candidate, ARV-110, for the treatment of prostate cancer, and has entered into a partnership with Pfizer for the development of additional PROTAC candidates. The North American PROTACs market is also characterized by a large number of academic and research institutions that are focused on developing new PROTACs and advancing the understanding of protein degradation as a therapeutic modality. For example, the University of Michigan has developed a novel class of PROTACs that target the androgen receptor for the treatment of prostate cancer, while the University of California, San Francisco is focused on developing PROTACs for the treatment of HIV.